Impel NeuroPharma’s POD device is designed to deliver drugs to the upper nasal cavity for improved distribution to the brain. By delivering therapeutics to the upper nasal cavity, the POD nasal device takes advantage of the vascular rich olfactory region for improved bioavailability and targets the brain via the olfactory and trigeminal nerves. Utilizing the POD device can enable a wide range of drugs, including biologics, to effectively treat CNS diseases. Delivery of therapeutically meaningful levels of drugs to the brain using POD technology allows for development of more effective drugs and expands the range of treatment options available to patients.
The proven direct-to-CNS delivery achievable using the POD occurs by taking advantage of the naturally occurring nose-to-brain pathway. Utilizing the POD device to bypass the blood-brain-barrier can enable a wide range of drugs to effectively treat CNS diseases. Delivery of therapeutically meaningful levels of drugs to the brain using POD technology, allows pharmaceutical companies to develop more effective drugs and expand the range of treatment options available to patients.
The POD devices are next generation nasal spray devices which offer:
• Low residual drug
• Unit dose or multidose
• Liquid and dry powder compatible
• No breath coordination required
• Adaptable for pediatric use
The POD platform can be used from early development through commercialization to help enable intranasal delivery of CNS acting drugs:
• Preclinical proof of concept studies performed at Impel’s labs
• POD devices transferred out for preclinical use at partner labs
• Toxicology studies
• Proof-of-concept in man trials
• Phase I, Phase II, Phase III clinical studies
• Commercial phase development with a drug program
The POD technology can be adapted to many different drug types. However, each drug is unique. Impel works on each program as a drug device combination product to ensure maximum performance and compatibility of POD for the dose, dosing regimen, and patient population.
Impel has an internal drug-device combination pipeline and is able to partner with pharmaceutical companies to develop new or existing compounds as a POD delivered intranasal formulation.
Impel offers the following expertise and assistance to its partners:
• Formulation development
• Drug-device compatibility testing
• Preclinical study design and execution
• Clinical study design and execution
• Regulatory assistance
Impel has developed POD devices for many stages of the drug development pathway. We have devices specifically designed for both preclinical and clinical studies ensuring continuity as the research progresses.
The POD technology has been used in numerous studies with various drugs. Impel has the capabilities to run preclinical studies in-house or work with external partners to test the POD technology.